Evaluate Pharma
@evaluatepharma
Followers
7K
Following
342
Media
3K
Statuses
7K
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.
London, Boston & Tokyo
Joined June 2009
Don’t miss our presentations at Pharma CI, featuring: Kelly Chamberlain, Partner, Market Intelligence at Evaluate, and Diane Gowe, Director, Global Strategic Analytics. Session: Supporting Cross-Functional Teams with Corporate-Level CI 📅 Let’s connect: https://t.co/yhGnI3Ybsv
0
0
0
Improve ROI from digital transformation in pharmaceutical forecasting with key processes like personalized approaches, strategic models, good communication, and integrated training. Learn more in this blog post: https://t.co/axJtQszNhB
1
0
1
Loss of exclusivity doesn’t have to mean lost opportunity. https://t.co/U4zmOEYbMw. As pricing and competition intensify, forecasting teams are key to managing lifecycle shifts. Our expert guide helps pharma teams navigate LoE before disruption hits.
0
0
1
https://t.co/8VMOKtP2SM | There are lots of sophisticated forecasting tools out there, so why do forecasters still use Excel? In this video blog, our forecasting guru, Andrew Ward, explains more about when and why Excel still has a place in the forecaster's toolkit. Watch now.
0
0
1
Missed launches and misaligned resources can cost pharma companies millions. https://t.co/JoOvRILZ1Y Our guide, Understands how to build reliable, adaptable pharma forecasts that reflect real-world market events. Don’t leave your next forecast to chance.
0
0
0
💡 The Q3 2025 Outlook Report is now Live! Powered by Biomedtracker and Meddevicetracker, it highlights: •Key FDA decisions and trial readouts •LOA data to support forecasting •M&A activity and strategic deal signals Download your copy: https://t.co/ArKdjnEan9
0
0
1
Heading to Pharma CI US this September? So are we and we’ve built a dedicated content hub to help you get the most out of it. https://t.co/iXLIsmatOY.
0
0
0
Explore how AI is revolutionizing the pharma industry - from drug discovery to clinical trials & diagnostics, on our blog. Are we close to making this promise a reality? Find out here in this blog post: https://t.co/N3NqrTyq3M
1
0
2
🔍 How can CI teams deliver more with less? https://t.co/XHCJ6iq6Ba In our latest report, we explore: ✅ Common challenges in CI design ✅ Strategies to balance stakeholder demands ✅ Best practices to boost strategic value
1
0
1
https://t.co/zxypYdcCwW | There are lots of sophisticated forecasting tools out there, so why do forecasters still use Excel? In this video blog, our forecasting guru, Andrew Ward, explains more about when and why Excel still has a place in the forecaster's toolkit. Watch now.
0
0
1
🔍 How can CI teams deliver more with less? https://t.co/1iKgZTga7I In our latest report, we explore: ✅ Common challenges in CI design ✅ Strategies to balance stakeholder demands ✅ Best practices to boost strategic value
1
0
1
AI adoption strategies are set to surge in 50% of global healthcare companies. This is predicted to boost new drug development by 40% annually, improving efficiency in drug discovery, clinical trials, and diagnostics. Read more in this blog post: https://t.co/Yapl5jXuZv
0
0
1
https://t.co/knaKfRhO2Y | Get the latest on GLP-1 dealmaking trends from Evaluate's Ben Folwell, at the recent Law & Policy Summit. Discover growth in investment, R&D updates, and China's role, covered in our latest blog post.
0
0
0
📊 The Q3 2025 Outlook Report is live! Built on Biomedtracker and Meddevicetracker intelligence, this report delivers 23 drug catalysts with LOA benchmarks, strategic deal activity, and Actionable insights for BD & pipeline strategy. 📥 Download now: https://t.co/hC5q4TE5As
0
0
1
Looking to find the right analogs for your revolutionary therapy? Check out this blog post that highlights the importance of past launch records and creative thinking to build a reliable, adaptable forecasting model. https://t.co/6wc0i27ynN
1
0
1
Many big pharma players are facing patent expiry in the next 5 years, and the pipeline is packed with competitive entrants. https://t.co/UPneacvlQF. Our latest forecasting insights explore how loss of exclusivity (LoE) and generic competition are reshaping market planning.
0
0
2
https://t.co/DXKT71i5rW | How did the second quarter fare for FDA approvals? In this exclusive new article for Nature Reviews Drug Discovery, Evaluate's Paul Verdin discusses the therapies that got the thumbs-up in the past three months. (Subscription may be required)
nature.com
Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com
0
0
0
NEW training course to help you master statistical trending! https://t.co/gQ9YZVASMa 📚 Understand trending theory 🤖 Select the right algorithms with confidence 💻 Apply your knowledge using Sales+ software Click the link to learn more & download the brochure.
0
0
1
The relationship between epidemiology forecasting and data sources is complex. Generating accurate forecasts relies heavily on data, and factors such as real-world data and artificial intelligence have an increasing impact. Learn more: https://t.co/QKo0OSs1ed
0
0
1
If you’re working in oncology or a complex therapeutic area, this new eBook chapter is for you. https://t.co/OIczTkpGkt Created by our forecasting experts, it shows how to model disease progression, factor in treatment restrictions, and align with real-world care pathways.
0
0
2